Outlook Therapeutics Names Greg DiPasquale Chief Commercial Officer
Outlook Therapeutics Inc OTLK
News
Outlook Therapeutics Highlights What the Appointment of New CFO Kevin Lundquist Means for the Company’s Next Chapter in Virtual Investor Discussion
Outlook Therapeutics Submits HCPCS Level II Application to CMS for Permanent J-Code for LYTENAVA™ (bevacizumab-vikg)
Outlook Therapeutics Fireside Chat from H.C. Wainwright Conference Now Available On-Demand
Outlook Therapeutics CEO, Bob Jahr, Discusses FDA Approval and Commercial Opportunity for LYTENAVA™ in Virtual Investor CEO Connect Segment
Outlook Therapeutics Appoints Kevin Lundquist as Chief Financial Officer as It Prepares for U.S. Commercial Launch of LYTENAVA™
Outlook Therapeutics CEO, Bob Jahr, Participates in the Virtual Investor “Why Now” On-Demand Conference
Outlook Therapeutics Reports Third Quarter Fiscal Year 2026 Financial Results and Provides Business Update Highlighting FDA Approval of LYTENAVA™
Outlook Therapeutics Announces Pricing of $55.0 Million Public Offering of Common Stock and Warrants
Outlook Therapeutics Announces Proposed Public Offering of Common Stock and Warrants
Outlook Therapeutics to Report Third Quarter Fiscal Year 2026 Financial Results and Host a Corporate Update Conference Call and Webcast on August 14, 2026
Outlook Therapeutics Gains Following FDA Approval of Macular-Degeneration Drug — Update
Outlook Therapeutics Shares Surge After FDA Accepts Resubmitted Wet AMD Application
Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug
Outlook Therapeutics Says FDA Didn't Approve Macular Degeneration Drug Application
United States